Epigenetics Drugs and Diagnostic Technologies Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

The global Epigenetics Drugs and Diagnostic Technologies market size is expected to be worth around US$ 6.24 billion by 2030, according to a new report by Vision Research Reports.

The global Epigenetics Drugs and Diagnostic Technologies market size was valued at US$ xx billion in 2020 and is anticipated to grow at a CAGR of 29.7% during forecast period 2021 to 2030.

Growth Factors

High prevalence of cancer and other chronic diseases along with rising geriatric population are some of the key factors expected to boost the market. Organizations, such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) promote funding and support to R&D and product development exercises pertaining to the field of epigenetics. This factor is anticipated to further fuel the expansion.

The NIH funds epigenetics research through the Common Fund Epigenomics program, which actively provides support for research, worldwide. Rising need to understand epigenetic modifications at the molecular level and development of therapeutic solutions are anticipated to motivate these organizations to fund R&D programs. In addition, endeavors such as the Epidemiology and Genomics Research Program (EGRP) in the NCI's Division of Cancer grants research 

Report Highlights

Reagents dominated the product segment of the epigenetics drugs and diagnostic technologies market in 2017. Histone and DNA modifiers are the major types of reagents. Epigenetic reagents are segmented into antibodies, PCR reagents, histones, primers, electrophoresis reagents, nucleic acid analysis reagents, buffers, and others.

The kits product segment was observed to be the fastest-growing segment over the forecast period. The ready-to-use kits are manufactured by many biotechnology companies for the detection of epigenetic modifications. Kits available in the market range from kits for nucleic acid purification, analysis of DNA methylation status, and detection of histone modifications by various enzymes to kits for chromatin immunoprecipitation.

Epigenetic diagnostic kits are used for the diagnosis of disorders due to epigenetic modifications in the early stages and during treatment to check the efficacy of therapeutics. They work on the basis of immunoprecipitation by the involvement of modification-specific monoclonal antibodies.

The technology segment can be categorized into DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification, and chromatin structures. DNA methylation was the largest segment in 2017. DNA methylation is the covalent addition of a methyl group in the cytosine ring, which leads to inhibition of transcription. Sensitive bisulphite modification followed by PCR is performed called Methylation Sensitive PCR (MSP).

Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are the variations of MSP. Currently, quantitative methods, such as allele-specific bisulphite sequencing, southern-based method, bisulphite pyrosequencing, and bisulphite PCR followed by MALDI-TOF MS are also useful for DNA methylation. Technological advancements are increasingly enabling the assessment of locus-specific DNA methylation on genome-wide scale.

Histone Acetylation is expected to witness the fastest growth over the forecast period. Their enhanced efficacy due to the introduction of novel mechanisms can be attributed to this growth. Histone acetylation is the enzymatic incorporation of an acetyl group to lysine residues.

Histone acetylation is involved in controlling cellular processes, such as gene silencing, chromatin transcription and dynamics, the progression of the cell cycle, differentiation, apoptosis, DNA replication, neuronal repression, nuclear import, and DNA repair. The enzymes involved in histone acetylation are Histone Acetyl Transferases (HATs) and the enzymes involved in deacetylation are Histone Deacetylases (HDACs).

Based on the type of epigenetic therapies, the market is segmented into Histone Deacetylase (HDAC) inhibitors and DNA Methyltransferase (DNMT) inhibitors. The DNMT inhibitors were the largest revenue-generating segment in 2017 owing to factors such as wide-scale availability in most regions. Furthermore, a high number of generics are available in this therapy class, which is anticipated to bode well for segment growth.

The HDAC inhibitors are estimated to be the fastest-growing segment over the forecast period, owing to factors such as the presence of strong product pipeline and commercial availability of the maximum number of products. In addition, from 2014 to 2015 three HDAC inhibitors were launched in the market, which is further likely to accelerate the growth of this therapy class over the forecast period.

Hypermethylation and epigenetic silencing are known as epimutations, occurring due to epigenetic changes. Epimutations have been known to be involved in the etiology of cancers. Extensive R&D for detecting epimutations, specifically related to the silencing of tumor suppressor genes and activation of oncogenes, is anticipated to create growth avenues.

Non-oncology is estimated to be the fastest-growing segment owing to rigorous R&D initiatives undertaken by private institutions and biopharmaceutical companies for the identification of epigenetic markers related to these disorders. Epigenetic modifications have been proved to be the base of metabolic, neurodegenerative, and infectious diseases and many other non-oncology disorders. Extensive research is undertaken by private institutions and biopharmaceutical companies for the detection of biomarkers for drug development.

North America is the dominant region segment of this market. It held over 39.34% of the market share in 2017. The presence of government funding programs for ongoing research activities, better healthcare facilities, and constantly growing geriatric population are some of the prominent driving factors. In addition, the Common Fund-supported programs in the U.S. are likely to boost the research activities for a broad range of oncology and non-oncology diseases including metabolic, inflammatory, cardiovascular, and other diseases.

Asia Pacific is estimated to be the fastest-growing region over the forecast period owing to the rising disposable income, high unmet clinical needs, rising awareness about early diagnosis, and availability of effective treatment in emerging countries, such as India and China. Asia Pacific is in limelight due to increasing cases of various types of cancers.

Key Players

Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; Novartis AG; Illumina, Inc.; Merck Sharp & Dohme Corp; Qiagen; Abcam PLC; and Merck KGaA

Market Segmentation

  • Product Outlook 

    • Reagents

    • Kits

      • ChIP Sequencing Kit

      • Whole Genomic Amplification Kit

      • Bisulfite Conversion Kit

      • RNA Sequencing Kit

      • Others

    • Instruments

    • Enzymes

    • Services

  • Technology Outlook 

    • DNA Methylation

    • Histone Methylation

    • Histone Acetylation

    • Large Non-coding RNA

    • MicroRNA Modification

    • Chromatin Structures

  • Type of Therapy Outlook 

    • Histone Deacetylase (HDAC) Inhibitors

    • DNA Methyltransferase (DNMT) Inhibitors

  • Application Outlook 

    • Oncology

      • Solid Tumors

      • Liquid Tumors

    • Non-oncology

      • Inflammatory Diseases

      • Metabolic Diseases

      • Infectious Diseases

      • Cardiovascular Diseases

      • Others

  • Regional Outlook 

    • North America

      • The U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

    • Asia Pacific

      • Japan

      • China

      • India

    • Latin America

      • Brazil

      • Mexico

    • MEA

      • South Africa

The Epigenetics Drugs and Diagnostic Technologies market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.

The report provides size (in terms of volume and value) of Epigenetics Drugs and Diagnostic Technologies market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.

This report focuses on the global Epigenetics Drugs and Diagnostic Technologies market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Epigenetics Drugs and Diagnostic Technologies market development in United States, Europe and China.

It is pertinent to consider that in a volatile global economy, we haven’t just conducted Epigenetics Drugs and Diagnostic Technologies market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.

In terms of production side, this report researches the Epigenetics Drugs and Diagnostic Technologies capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.

In terms of consumption side, this report focuses on the consumption of Epigenetics Drugs and Diagnostic Technologies by regions (countries) and application.

Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Epigenetics Drugs and Diagnostic Technologies market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.

With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Epigenetics Drugs and Diagnostic Technologies market companies.

Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Epigenetics Drugs and Diagnostic Technologies market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.

The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.

Overall, this is an in-depth research report specifically for the Epigenetics Drugs and Diagnostic Technologies industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.

The Epigenetics Drugs and Diagnostic Technologies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Epigenetics Drugs and Diagnostic Technologies market.

Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Epigenetics Drugs and Diagnostic Technologies market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.

Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Epigenetics Drugs and Diagnostic Technologies market. These factors have benefited the growth of the global market for Epigenetics Drugs and Diagnostic Technologies. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.

New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Epigenetics Drugs and Diagnostic Technologies. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).

In this study, the years considered to estimate the market size of Epigenetics Drugs and Diagnostic Technologies are as follows:

  • Historic Year: 2017-2020
  • Base Year: 2021
  • Forecast Year 2021 to 2030

Reasons to Purchase this Report:

- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Research Methodology:

In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Market Size Estimation

Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).

The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.

Secondary Sources

Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.

Primary Sources

 In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.

The study objectives of this report are:

  • To analyze and study the global market capacity, production, value, consumption, status (2017-2020) and forecast (2021-2030);
  • Focuses on the key manufacturers, to study the capacity, production, value, market share and development plans in future.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • To define, describe and forecast the market by type, application and region.
  • To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
  • To identify significant trends and factors driving or inhibiting the market growth.
  • To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
  • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
  • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
  • To strategically profile the key players and comprehensively analyze their growth strategies.

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Epigenetics Drugs and Diagnostic Technologies Market, By Product

7.1.  Epigenetics Drugs and Diagnostic Technologies Market, By Product, 2020-2028

7.1.1.    Reagents

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Kits

7.1.2.1.        Market Revenue and Forecast (2016-2028)

7.1.3.    Instruments

7.1.3.1.        Market Revenue and Forecast (2016-2028)

7.1.4.    Enzymes

7.1.4.1.        Market Revenue and Forecast (2016-2028)

7.1.5.    Services

7.1.5.1.        Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Epigenetics Drugs and Diagnostic Technologies Market, By Technology

8.1.  Epigenetics Drugs and Diagnostic Technologies Market, By Technology, 2020-2028

8.1.1.    DNA Methylation

8.1.1.1.        Market Revenue and Forecast (2016-2028)

8.1.2.    Histone Methylation

8.1.2.1.        Market Revenue and Forecast (2016-2028)

8.1.3.    Histone Acetylation

8.1.3.1.        Market Revenue and Forecast (2016-2028)

8.1.4.    Large Non-coding RNA

8.1.4.1.        Market Revenue and Forecast (2016-2028)

8.1.5.    MicroRNA Modification

8.1.5.1.        Market Revenue and Forecast (2016-2028)

8.1.6.    Chromatin Structures

8.1.6.1.        Market Revenue and Forecast (2016-2028)

Chapter 9.  Global Epigenetics Drugs and Diagnostic Technologies Market, By Type of Therapy

9.1.  Epigenetics Drugs and Diagnostic Technologies Market, By Type of Therapy, 2020-2028

9.1.1.    Histone Deacetylase (HDAC) Inhibitors

9.1.1.1.        Market Revenue and Forecast (2016-2028)

9.1.2.    DNA Methyltransferase (DNMT) Inhibitors

9.1.2.1.        Market Revenue and Forecast (2016-2028)

Chapter 10.      Global Epigenetics Drugs and Diagnostic Technologies Market, By Capacitor

10.1.        Epigenetics Drugs and Diagnostic Technologies Market, by Capacitor, 2020-2028

10.1.1.  Oncology

10.1.1.1.      Market Revenue and Forecast (2016-2028)

10.1.2.  Non-oncology

10.1.2.1.      Market Revenue and Forecast (2016-2028)

Chapter 11.      Global Epigenetics Drugs and Diagnostic Technologies Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, By Product (2016-2028)

11.1.2.  Market Revenue and Forecast, By Technology (2016-2028)

11.1.3.  Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.1.4.  Market Revenue and Forecast, by Capacitor (2016-2028)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, By Product (2016-2028)

11.1.5.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.1.5.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.1.5.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, By Product (2016-2028)

11.1.6.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.1.6.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.1.6.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, By Product (2016-2028)

11.2.2.  Market Revenue and Forecast, By Technology (2016-2028)

11.2.3.  Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.2.4.  Market Revenue and Forecast, by Capacitor (2016-2028)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, By Product (2016-2028)

11.2.5.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.2.5.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.2.5.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, By Product (2016-2028)

11.2.6.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.2.6.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.2.6.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, By Product (2016-2028)

11.2.7.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.2.7.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.2.7.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, By Product (2016-2028)

11.2.8.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.2.8.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.2.8.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, By Product (2016-2028)

11.3.2.  Market Revenue and Forecast, By Technology (2016-2028)

11.3.3.  Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.3.4.  Market Revenue and Forecast, by Capacitor (2016-2028)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, By Product (2016-2028)

11.3.5.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.3.5.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.3.5.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, By Product (2016-2028)

11.3.6.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.3.6.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.3.6.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, By Product (2016-2028)

11.3.7.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.3.7.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.3.7.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, By Product (2016-2028)

11.3.8.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.3.8.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.3.8.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, By Product (2016-2028)

11.4.2.  Market Revenue and Forecast, By Technology (2016-2028)

11.4.3.  Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.4.4.  Market Revenue and Forecast, by Capacitor (2016-2028)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, By Product (2016-2028)

11.4.5.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.4.5.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.4.5.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, By Product (2016-2028)

11.4.6.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.4.6.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.4.6.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, By Product (2016-2028)

11.4.7.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.4.7.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.4.7.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, By Product (2016-2028)

11.4.8.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.4.8.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.4.8.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, By Product (2016-2028)

11.5.2.  Market Revenue and Forecast, By Technology (2016-2028)

11.5.3.  Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.5.4.  Market Revenue and Forecast, by Capacitor (2016-2028)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, By Product (2016-2028)

11.5.5.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.5.5.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.5.5.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, By Product (2016-2028)

11.5.6.2.      Market Revenue and Forecast, By Technology (2016-2028)

11.5.6.3.      Market Revenue and Forecast, By Type of Therapy (2016-2028)

11.5.6.4.      Market Revenue and Forecast, by Capacitor (2016-2028)

Chapter 12.  Company Profiles

12.1.              Roche Diagnostics

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Thermo Fisher Scientific, Inc.

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Eisai Co. Ltd.

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Novartis AG

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Illumina, Inc.

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Merck Sharp & Dohme Corp

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Qiagen

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Abcam PLC

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Merck KGaA

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers